Cidara's weekly antifungal candidate rolls toward Phase II

Cidara Therapeutics' ($CDTX) once-a-week antifungal therapy came through in the first of two Phase I trials, emboldening the company to press ahead with its lead therapy. The drug, CD101, is an intravenous treatment for invasive fungal infections including candidemia. In a single ascending-dose trial on 32 healthy volunteers, the drug was well-tolerated with no serious side effects, Cidara said, and demonstrated a pharmacokinetic profile consistent with preclinical studies. Now the company is waiting on results from a multiple ascending-dose study, slated to report out early next year, and blueprinting a Phase II trail in candidemia in the first half of 2016. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.